Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01331590 · ClinicalTrials.gov registry record · Early Phase 1
Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic Leukemia
A Early Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 13
- Enrollment target
NCT01331590: Completed Early Phase 1 study, sponsored by Washington University School of Medicine.
NCT01331590 is a Early Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 13 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01331590, a Early Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the ability of G-CSF to disrupt the bone marrow microenvironment as a means to increase the efficacy of chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia (ALL).
Interventions
- DRUG Mesna
- DRUG G-CSF
- DRUG Etoposide
- DRUG Dexamethasone
- DRUG Ifosfamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2011-07 |
| Est. Completion | 2015-11 |
| Phase | Early Phase 1 |
What the finished NCT01331590 record still lists
NCT01331590 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 5 interventions - of which Mesna is the first listed.
NCT01331590 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01331590 about?
NCT01331590 is a clinical study titled "Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic Leukemia". The purpose of this study is to determine the ability of G-CSF to disrupt the bone marrow microenvironment as a means to increase the efficacy of chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia (ALL).
What is the current status of trial NCT01331590?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 13 participants. The study started on 2011-07. Estimated completion is 2015-11.
What interventions are being tested in trial NCT01331590?
The interventions under investigation include: Mesna (DRUG), G-CSF (DRUG), Etoposide (DRUG), Dexamethasone (DRUG), Ifosfamide (DRUG).
Who is sponsoring clinical trial NCT01331590?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01331590's enrollment target sits among peer trials
13 1503rd of 2000 higher than 472 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia